摘要Background:The full-thickness excision of malignant lower-eyelid tumors,particularly those with posterior lamellar involvement,presents a reconstructive challenge.Traditional grafts often have limitations,prompting interest in biocompatible alternatives,such as biodegradable diplene membranes.This study introduces a novel modification to the standard protocol:the use of diplene membranes enriched with Solcoseryl,a metabolically active agent that enhances angiogenesis,reduces inflammation,and accelerates epithelialization.Methods:Twenty-seven patients(mean age,68.96±8.09 years)with histologically confirmed malignant lower-eyelid tumors underwent reconstruction using diplene membranes combined with Solcoseryl.The outcomes were compared with those of a previously reported cohort treated with Diplene alone.The follow-up period ranged from 3 to 12 months.Results:All patients achieved successful restoration of eyelid support with high aesthetic satisfaction.The Sol-coseryl group demonstrated significantly faster epithelialization(mean 9.8±1.2 days),improved microcircu-latory parameters,and no serious complications.Minor hematomas occurred in two cases(7.4％).Conclusion:The modified Diplene-Solcoseryl membrane enhanced wound healing and biocompatibility during lower-eyelid reconstruction by transforming the membrane into a bioactive scaffold.This innovation offers su-perior functional and aesthetic outcomes compared to standard diplene use and represents a significant advancement in oculoplastic and oncological reconstructive surgery.